nodes	percent_of_prediction	percent_of_DWPC	metapath
Raloxifene—CYP19A1—Paclitaxel—kidney cancer	0.101	0.173	CbGbCtD
Raloxifene—HTR2B—Sorafenib—kidney cancer	0.0916	0.157	CbGbCtD
Raloxifene—CYP3A4—Everolimus—kidney cancer	0.0552	0.0947	CbGbCtD
Raloxifene—CYP2C8—Pazopanib—kidney cancer	0.0483	0.0828	CbGbCtD
Raloxifene—CYP3A4—Temsirolimus—kidney cancer	0.0373	0.064	CbGbCtD
Raloxifene—CYP2B6—Sorafenib—kidney cancer	0.037	0.0635	CbGbCtD
Raloxifene—CYP2C8—Erlotinib—kidney cancer	0.0345	0.0591	CbGbCtD
Raloxifene—CYP2C8—Paclitaxel—kidney cancer	0.0316	0.0541	CbGbCtD
Raloxifene—CYP2C8—Sorafenib—kidney cancer	0.028	0.0481	CbGbCtD
Raloxifene—CYP2B6—Doxorubicin—kidney cancer	0.0225	0.0385	CbGbCtD
Raloxifene—CYP3A4—Pazopanib—kidney cancer	0.0196	0.0336	CbGbCtD
Raloxifene—CYP3A4—Erlotinib—kidney cancer	0.014	0.024	CbGbCtD
Raloxifene—CYP3A4—Paclitaxel—kidney cancer	0.0128	0.0219	CbGbCtD
Raloxifene—CYP3A4—Sorafenib—kidney cancer	0.0114	0.0195	CbGbCtD
Raloxifene—CYP3A4—Vinblastine—kidney cancer	0.0112	0.0193	CbGbCtD
Raloxifene—CYP3A4—Vincristine—kidney cancer	0.011	0.0189	CbGbCtD
Raloxifene—CYP3A4—Sunitinib—kidney cancer	0.00921	0.0158	CbGbCtD
Raloxifene—CYP3A4—Doxorubicin—kidney cancer	0.0069	0.0118	CbGbCtD
Raloxifene—CYP3A4—urine—kidney cancer	0.002	0.0799	CbGeAlD
Raloxifene—EBP—Temsirolimus—Everolimus—kidney cancer	0.00191	0.306	CbGdCrCtD
Raloxifene—EBP—Sirolimus—Everolimus—kidney cancer	0.00191	0.306	CbGdCrCtD
Raloxifene—EBP—Sirolimus—Temsirolimus—kidney cancer	0.00191	0.306	CbGdCrCtD
Raloxifene—AOX1—nephron tubule—kidney cancer	0.00136	0.0542	CbGeAlD
Raloxifene—ESR2—renal system—kidney cancer	0.00128	0.0512	CbGeAlD
Raloxifene—ESR2—kidney—kidney cancer	0.00124	0.0495	CbGeAlD
Raloxifene—AOX1—renal system—kidney cancer	0.00123	0.0492	CbGeAlD
Raloxifene—AOX1—kidney—kidney cancer	0.00119	0.0476	CbGeAlD
Raloxifene—AOX1—cortex of kidney—kidney cancer	0.00116	0.0464	CbGeAlD
Raloxifene—ESR2—gonad—kidney cancer	0.00115	0.0459	CbGeAlD
Raloxifene—AOX1—gonad—kidney cancer	0.00111	0.0442	CbGeAlD
Raloxifene—AOX1—cardiac atrium—kidney cancer	0.00111	0.0441	CbGeAlD
Raloxifene—SIGMAR1—nephron tubule—kidney cancer	0.00109	0.0436	CbGeAlD
Raloxifene—SIGMAR1—cortex of kidney—kidney cancer	0.000936	0.0373	CbGeAlD
Raloxifene—HTR2B—cortex of kidney—kidney cancer	0.000934	0.0372	CbGeAlD
Raloxifene—CYP19A1—gonad—kidney cancer	0.000907	0.0362	CbGeAlD
Raloxifene—SIGMAR1—cardiac atrium—kidney cancer	0.00089	0.0355	CbGeAlD
Raloxifene—ESR1—renal system—kidney cancer	0.000879	0.035	CbGeAlD
Raloxifene—ESR1—kidney—kidney cancer	0.000849	0.0339	CbGeAlD
Raloxifene—ESR1—gonad—kidney cancer	0.000788	0.0314	CbGeAlD
Raloxifene—CYP2C8—renal system—kidney cancer	0.000724	0.0289	CbGeAlD
Raloxifene—CYP2B6—nephron tubule—kidney cancer	0.000714	0.0285	CbGeAlD
Raloxifene—CYP2C8—kidney—kidney cancer	0.0007	0.0279	CbGeAlD
Raloxifene—CYP2B6—renal system—kidney cancer	0.000649	0.0259	CbGeAlD
Raloxifene—CYP2B6—kidney—kidney cancer	0.000628	0.025	CbGeAlD
Raloxifene—CYP2B6—gonad—kidney cancer	0.000582	0.0232	CbGeAlD
Raloxifene—EBP—Azacitidine—Gemcitabine—kidney cancer	0.000514	0.0823	CbGdCrCtD
Raloxifene—CYP3A4—renal system—kidney cancer	0.00049	0.0196	CbGeAlD
Raloxifene—CYP3A4—kidney—kidney cancer	0.000474	0.0189	CbGeAlD
Raloxifene—Body temperature increased—Everolimus—kidney cancer	0.00032	0.00111	CcSEcCtD
Raloxifene—Gastrointestinal pain—Erlotinib—kidney cancer	0.000319	0.00111	CcSEcCtD
Raloxifene—Hypoaesthesia—Paclitaxel—kidney cancer	0.000318	0.00111	CcSEcCtD
Raloxifene—Infection—Dactinomycin—kidney cancer	0.000318	0.00111	CcSEcCtD
Raloxifene—Vaginal infection—Doxorubicin—kidney cancer	0.000318	0.00111	CcSEcCtD
Raloxifene—Pharyngitis—Paclitaxel—kidney cancer	0.000317	0.0011	CcSEcCtD
Raloxifene—Urinary tract disorder—Paclitaxel—kidney cancer	0.000316	0.0011	CcSEcCtD
Raloxifene—Bronchitis—Capecitabine—kidney cancer	0.000315	0.0011	CcSEcCtD
Raloxifene—Oedema peripheral—Paclitaxel—kidney cancer	0.000315	0.0011	CcSEcCtD
Raloxifene—Vertigo—Vincristine—kidney cancer	0.000315	0.0011	CcSEcCtD
Raloxifene—Connective tissue disorder—Paclitaxel—kidney cancer	0.000314	0.00109	CcSEcCtD
Raloxifene—Urethral disorder—Paclitaxel—kidney cancer	0.000313	0.00109	CcSEcCtD
Raloxifene—Thrombocytopenia—Dactinomycin—kidney cancer	0.000313	0.00109	CcSEcCtD
Raloxifene—Cramps of lower extremities—Doxorubicin—kidney cancer	0.000309	0.00108	CcSEcCtD
Raloxifene—Dyspepsia—Sorafenib—kidney cancer	0.000309	0.00108	CcSEcCtD
Raloxifene—Abdominal pain—Erlotinib—kidney cancer	0.000309	0.00107	CcSEcCtD
Raloxifene—Body temperature increased—Erlotinib—kidney cancer	0.000309	0.00107	CcSEcCtD
Raloxifene—Musculoskeletal discomfort—Sunitinib—kidney cancer	0.000308	0.00107	CcSEcCtD
Raloxifene—Insomnia—Sunitinib—kidney cancer	0.000306	0.00106	CcSEcCtD
Raloxifene—Nausea—Pazopanib—kidney cancer	0.000304	0.00106	CcSEcCtD
Raloxifene—Bladder pain—Doxorubicin—kidney cancer	0.000304	0.00106	CcSEcCtD
Raloxifene—Gastrointestinal disorder—Sorafenib—kidney cancer	0.000303	0.00106	CcSEcCtD
Raloxifene—Pain—Sorafenib—kidney cancer	0.0003	0.00105	CcSEcCtD
Raloxifene—Myalgia—Vincristine—kidney cancer	0.000298	0.00104	CcSEcCtD
Raloxifene—Weight increased—Capecitabine—kidney cancer	0.000298	0.00104	CcSEcCtD
Raloxifene—Dyspepsia—Sunitinib—kidney cancer	0.000298	0.00104	CcSEcCtD
Raloxifene—Cardiac disorder—Paclitaxel—kidney cancer	0.000297	0.00103	CcSEcCtD
Raloxifene—Flushing—Paclitaxel—kidney cancer	0.000297	0.00103	CcSEcCtD
Raloxifene—Pneumonia—Capecitabine—kidney cancer	0.000294	0.00102	CcSEcCtD
Raloxifene—Gastrointestinal disorder—Sunitinib—kidney cancer	0.000292	0.00102	CcSEcCtD
Raloxifene—Musculoskeletal discomfort—Dactinomycin—kidney cancer	0.000292	0.00101	CcSEcCtD
Raloxifene—Depression—Capecitabine—kidney cancer	0.000291	0.00101	CcSEcCtD
Raloxifene—Cough—Gemcitabine—kidney cancer	0.00029	0.00101	CcSEcCtD
Raloxifene—Angiopathy—Paclitaxel—kidney cancer	0.00029	0.00101	CcSEcCtD
Raloxifene—Pain—Sunitinib—kidney cancer	0.000289	0.00101	CcSEcCtD
Raloxifene—Gastrointestinal pain—Sorafenib—kidney cancer	0.000287	0.001	CcSEcCtD
Raloxifene—Infection—Vincristine—kidney cancer	0.000284	0.000989	CcSEcCtD
Raloxifene—Urinary tract infection—Capecitabine—kidney cancer	0.000284	0.000989	CcSEcCtD
Raloxifene—Conjunctivitis—Capecitabine—kidney cancer	0.000284	0.000989	CcSEcCtD
Raloxifene—Myalgia—Gemcitabine—kidney cancer	0.000283	0.000985	CcSEcCtD
Raloxifene—Chest pain—Gemcitabine—kidney cancer	0.000283	0.000985	CcSEcCtD
Raloxifene—Arthralgia—Gemcitabine—kidney cancer	0.000283	0.000985	CcSEcCtD
Raloxifene—Diabetes mellitus—Doxorubicin—kidney cancer	0.000281	0.000978	CcSEcCtD
Raloxifene—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—kidney cancer	0.000281	0.000978	CcSEcCtD
Raloxifene—Nervous system disorder—Vincristine—kidney cancer	0.00028	0.000976	CcSEcCtD
Raloxifene—Thrombocytopenia—Vincristine—kidney cancer	0.00028	0.000974	CcSEcCtD
Raloxifene—Diarrhoea—Vinblastine—kidney cancer	0.000278	0.000967	CcSEcCtD
Raloxifene—Abdominal pain—Sorafenib—kidney cancer	0.000278	0.000967	CcSEcCtD
Raloxifene—Body temperature increased—Sorafenib—kidney cancer	0.000278	0.000967	CcSEcCtD
Raloxifene—Diarrhoea—Everolimus—kidney cancer	0.000277	0.000964	CcSEcCtD
Raloxifene—Gastrointestinal pain—Sunitinib—kidney cancer	0.000276	0.000962	CcSEcCtD
Raloxifene—Hyperhidrosis—Vincristine—kidney cancer	0.000276	0.000962	CcSEcCtD
Raloxifene—Flatulence—Paclitaxel—kidney cancer	0.000274	0.000954	CcSEcCtD
Raloxifene—Pain—Dactinomycin—kidney cancer	0.000274	0.000952	CcSEcCtD
Raloxifene—Infection—Gemcitabine—kidney cancer	0.000269	0.000938	CcSEcCtD
Raloxifene—Dizziness—Vinblastine—kidney cancer	0.000269	0.000935	CcSEcCtD
Raloxifene—Dizziness—Everolimus—kidney cancer	0.000268	0.000931	CcSEcCtD
Raloxifene—Muscle spasms—Paclitaxel—kidney cancer	0.000267	0.000931	CcSEcCtD
Raloxifene—Abdominal pain—Sunitinib—kidney cancer	0.000267	0.00093	CcSEcCtD
Raloxifene—Body temperature increased—Sunitinib—kidney cancer	0.000267	0.00093	CcSEcCtD
Raloxifene—Diarrhoea—Erlotinib—kidney cancer	0.000267	0.00093	CcSEcCtD
Raloxifene—Nervous system disorder—Gemcitabine—kidney cancer	0.000266	0.000926	CcSEcCtD
Raloxifene—Thrombocytopenia—Gemcitabine—kidney cancer	0.000266	0.000924	CcSEcCtD
Raloxifene—Skin disorder—Gemcitabine—kidney cancer	0.000263	0.000917	CcSEcCtD
Raloxifene—Rhinitis—Capecitabine—kidney cancer	0.000263	0.000915	CcSEcCtD
Raloxifene—Hyperhidrosis—Gemcitabine—kidney cancer	0.000262	0.000913	CcSEcCtD
Raloxifene—Gastrointestinal pain—Dactinomycin—kidney cancer	0.000262	0.000911	CcSEcCtD
Raloxifene—Hot flush—Doxorubicin—kidney cancer	0.000261	0.000909	CcSEcCtD
Raloxifene—Hypoaesthesia—Capecitabine—kidney cancer	0.000261	0.000908	CcSEcCtD
Raloxifene—Musculoskeletal discomfort—Vincristine—kidney cancer	0.00026	0.000907	CcSEcCtD
Raloxifene—Pharyngitis—Capecitabine—kidney cancer	0.00026	0.000906	CcSEcCtD
Raloxifene—Urinary tract disorder—Capecitabine—kidney cancer	0.000259	0.000902	CcSEcCtD
Raloxifene—Menopausal symptoms—Doxorubicin—kidney cancer	0.000259	0.000902	CcSEcCtD
Raloxifene—Insomnia—Vincristine—kidney cancer	0.000259	0.0009	CcSEcCtD
Raloxifene—Oedema peripheral—Capecitabine—kidney cancer	0.000258	0.000899	CcSEcCtD
Raloxifene—Vomiting—Vinblastine—kidney cancer	0.000258	0.000899	CcSEcCtD
Raloxifene—Dizziness—Erlotinib—kidney cancer	0.000258	0.000899	CcSEcCtD
Raloxifene—Connective tissue disorder—Capecitabine—kidney cancer	0.000258	0.000897	CcSEcCtD
Raloxifene—Vomiting—Everolimus—kidney cancer	0.000257	0.000896	CcSEcCtD
Raloxifene—Urethral disorder—Capecitabine—kidney cancer	0.000257	0.000895	CcSEcCtD
Raloxifene—Rash—Everolimus—kidney cancer	0.000255	0.000888	CcSEcCtD
Raloxifene—Dermatitis—Everolimus—kidney cancer	0.000255	0.000887	CcSEcCtD
Raloxifene—Headache—Vinblastine—kidney cancer	0.000254	0.000886	CcSEcCtD
Raloxifene—Headache—Everolimus—kidney cancer	0.000253	0.000882	CcSEcCtD
Raloxifene—Body temperature increased—Dactinomycin—kidney cancer	0.000253	0.00088	CcSEcCtD
Raloxifene—Abdominal pain—Dactinomycin—kidney cancer	0.000253	0.00088	CcSEcCtD
Raloxifene—Vertigo—Paclitaxel—kidney cancer	0.00025	0.00087	CcSEcCtD
Raloxifene—Syncope—Paclitaxel—kidney cancer	0.000249	0.000868	CcSEcCtD
Raloxifene—Cerebrovascular accident—Doxorubicin—kidney cancer	0.000249	0.000868	CcSEcCtD
Raloxifene—Vomiting—Erlotinib—kidney cancer	0.000248	0.000864	CcSEcCtD
Raloxifene—Musculoskeletal discomfort—Gemcitabine—kidney cancer	0.000247	0.00086	CcSEcCtD
Raloxifene—Gastrointestinal disorder—Vincristine—kidney cancer	0.000247	0.000859	CcSEcCtD
Raloxifene—Rash—Erlotinib—kidney cancer	0.000246	0.000857	CcSEcCtD
Raloxifene—Dermatitis—Erlotinib—kidney cancer	0.000246	0.000856	CcSEcCtD
Raloxifene—Insomnia—Gemcitabine—kidney cancer	0.000245	0.000854	CcSEcCtD
Raloxifene—Headache—Erlotinib—kidney cancer	0.000245	0.000851	CcSEcCtD
Raloxifene—Loss of consciousness—Paclitaxel—kidney cancer	0.000245	0.000851	CcSEcCtD
Raloxifene—Pain—Vincristine—kidney cancer	0.000244	0.000851	CcSEcCtD
Raloxifene—Cardiac disorder—Capecitabine—kidney cancer	0.000243	0.000847	CcSEcCtD
Raloxifene—Flushing—Capecitabine—kidney cancer	0.000243	0.000847	CcSEcCtD
Raloxifene—Cough—Paclitaxel—kidney cancer	0.000243	0.000845	CcSEcCtD
Raloxifene—Nausea—Vinblastine—kidney cancer	0.000241	0.00084	CcSEcCtD
Raloxifene—Migraine—Doxorubicin—kidney cancer	0.000241	0.000837	CcSEcCtD
Raloxifene—Nausea—Everolimus—kidney cancer	0.00024	0.000837	CcSEcCtD
Raloxifene—Diarrhoea—Sorafenib—kidney cancer	0.00024	0.000837	CcSEcCtD
Raloxifene—Angiopathy—Capecitabine—kidney cancer	0.000238	0.000828	CcSEcCtD
Raloxifene—Arthralgia—Paclitaxel—kidney cancer	0.000237	0.000824	CcSEcCtD
Raloxifene—Myalgia—Paclitaxel—kidney cancer	0.000237	0.000824	CcSEcCtD
Raloxifene—Chest pain—Paclitaxel—kidney cancer	0.000237	0.000824	CcSEcCtD
Raloxifene—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—kidney cancer	0.000235	0.000819	CcSEcCtD
Raloxifene—Gastrointestinal disorder—Gemcitabine—kidney cancer	0.000234	0.000815	CcSEcCtD
Raloxifene—Gastrointestinal pain—Vincristine—kidney cancer	0.000234	0.000814	CcSEcCtD
Raloxifene—Dizziness—Sorafenib—kidney cancer	0.000232	0.000809	CcSEcCtD
Raloxifene—Pain—Gemcitabine—kidney cancer	0.000232	0.000807	CcSEcCtD
Raloxifene—Nausea—Erlotinib—kidney cancer	0.000232	0.000807	CcSEcCtD
Raloxifene—Diarrhoea—Sunitinib—kidney cancer	0.000231	0.000805	CcSEcCtD
Raloxifene—Abdominal pain—Vincristine—kidney cancer	0.000226	0.000787	CcSEcCtD
Raloxifene—Body temperature increased—Vincristine—kidney cancer	0.000226	0.000787	CcSEcCtD
Raloxifene—Infection—Paclitaxel—kidney cancer	0.000226	0.000785	CcSEcCtD
Raloxifene—Flatulence—Capecitabine—kidney cancer	0.000225	0.000783	CcSEcCtD
Raloxifene—Dizziness—Sunitinib—kidney cancer	0.000223	0.000778	CcSEcCtD
Raloxifene—Shock—Paclitaxel—kidney cancer	0.000223	0.000778	CcSEcCtD
Raloxifene—Vomiting—Sorafenib—kidney cancer	0.000223	0.000777	CcSEcCtD
Raloxifene—Nervous system disorder—Paclitaxel—kidney cancer	0.000223	0.000775	CcSEcCtD
Raloxifene—Thrombocytopenia—Paclitaxel—kidney cancer	0.000222	0.000774	CcSEcCtD
Raloxifene—Rash—Sorafenib—kidney cancer	0.000221	0.000771	CcSEcCtD
Raloxifene—Dermatitis—Sorafenib—kidney cancer	0.000221	0.00077	CcSEcCtD
Raloxifene—Breast disorder—Doxorubicin—kidney cancer	0.000221	0.000769	CcSEcCtD
Raloxifene—Skin disorder—Paclitaxel—kidney cancer	0.000221	0.000768	CcSEcCtD
Raloxifene—Aspartate aminotransferase increased—Doxorubicin—kidney cancer	0.00022	0.000766	CcSEcCtD
Raloxifene—Headache—Sorafenib—kidney cancer	0.00022	0.000766	CcSEcCtD
Raloxifene—Muscle spasms—Capecitabine—kidney cancer	0.00022	0.000764	CcSEcCtD
Raloxifene—Hyperhidrosis—Paclitaxel—kidney cancer	0.000219	0.000764	CcSEcCtD
Raloxifene—Diarrhoea—Dactinomycin—kidney cancer	0.000219	0.000762	CcSEcCtD
Raloxifene—Vomiting—Sunitinib—kidney cancer	0.000215	0.000748	CcSEcCtD
Raloxifene—Body temperature increased—Gemcitabine—kidney cancer	0.000214	0.000746	CcSEcCtD
Raloxifene—Rash—Sunitinib—kidney cancer	0.000213	0.000742	CcSEcCtD
Raloxifene—Dermatitis—Sunitinib—kidney cancer	0.000213	0.000741	CcSEcCtD
Raloxifene—Headache—Sunitinib—kidney cancer	0.000212	0.000737	CcSEcCtD
Raloxifene—Influenza—Doxorubicin—kidney cancer	0.000211	0.000735	CcSEcCtD
Raloxifene—Nausea—Sorafenib—kidney cancer	0.000209	0.000726	CcSEcCtD
Raloxifene—Musculoskeletal discomfort—Paclitaxel—kidney cancer	0.000207	0.00072	CcSEcCtD
Raloxifene—Insomnia—Paclitaxel—kidney cancer	0.000205	0.000715	CcSEcCtD
Raloxifene—Vertigo—Capecitabine—kidney cancer	0.000205	0.000714	CcSEcCtD
Raloxifene—Syncope—Capecitabine—kidney cancer	0.000205	0.000713	CcSEcCtD
Raloxifene—Vomiting—Dactinomycin—kidney cancer	0.000203	0.000708	CcSEcCtD
Raloxifene—Bronchitis—Doxorubicin—kidney cancer	0.000203	0.000707	CcSEcCtD
Raloxifene—Rash—Dactinomycin—kidney cancer	0.000202	0.000702	CcSEcCtD
Raloxifene—Nausea—Sunitinib—kidney cancer	0.000201	0.000699	CcSEcCtD
Raloxifene—Loss of consciousness—Capecitabine—kidney cancer	0.000201	0.000699	CcSEcCtD
Raloxifene—Dyspepsia—Paclitaxel—kidney cancer	0.0002	0.000696	CcSEcCtD
Raloxifene—Cough—Capecitabine—kidney cancer	0.000199	0.000694	CcSEcCtD
Raloxifene—Gastrointestinal disorder—Paclitaxel—kidney cancer	0.000196	0.000682	CcSEcCtD
Raloxifene—Diarrhoea—Vincristine—kidney cancer	0.000196	0.000681	CcSEcCtD
Raloxifene—Chest pain—Capecitabine—kidney cancer	0.000194	0.000677	CcSEcCtD
Raloxifene—Myalgia—Capecitabine—kidney cancer	0.000194	0.000677	CcSEcCtD
Raloxifene—Arthralgia—Capecitabine—kidney cancer	0.000194	0.000677	CcSEcCtD
Raloxifene—Pain—Paclitaxel—kidney cancer	0.000194	0.000676	CcSEcCtD
Raloxifene—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	0.000193	0.000672	CcSEcCtD
Raloxifene—Weight increased—Doxorubicin—kidney cancer	0.000192	0.000669	CcSEcCtD
Raloxifene—Nausea—Dactinomycin—kidney cancer	0.00019	0.000662	CcSEcCtD
Raloxifene—Pneumonia—Doxorubicin—kidney cancer	0.000189	0.000659	CcSEcCtD
Raloxifene—Dizziness—Vincristine—kidney cancer	0.000189	0.000658	CcSEcCtD
Raloxifene—Gastrointestinal pain—Paclitaxel—kidney cancer	0.000186	0.000646	CcSEcCtD
Raloxifene—Diarrhoea—Gemcitabine—kidney cancer	0.000186	0.000646	CcSEcCtD
Raloxifene—Infection—Capecitabine—kidney cancer	0.000185	0.000644	CcSEcCtD
Raloxifene—Shock—Capecitabine—kidney cancer	0.000183	0.000638	CcSEcCtD
Raloxifene—Urinary tract infection—Doxorubicin—kidney cancer	0.000183	0.000637	CcSEcCtD
Raloxifene—Conjunctivitis—Doxorubicin—kidney cancer	0.000183	0.000637	CcSEcCtD
Raloxifene—Nervous system disorder—Capecitabine—kidney cancer	0.000183	0.000636	CcSEcCtD
Raloxifene—Thrombocytopenia—Capecitabine—kidney cancer	0.000182	0.000635	CcSEcCtD
Raloxifene—Vomiting—Vincristine—kidney cancer	0.000182	0.000633	CcSEcCtD
Raloxifene—Skin disorder—Capecitabine—kidney cancer	0.000181	0.00063	CcSEcCtD
Raloxifene—Sweating—Doxorubicin—kidney cancer	0.000181	0.000628	CcSEcCtD
Raloxifene—Rash—Vincristine—kidney cancer	0.00018	0.000627	CcSEcCtD
Raloxifene—Hyperhidrosis—Capecitabine—kidney cancer	0.00018	0.000627	CcSEcCtD
Raloxifene—Dermatitis—Vincristine—kidney cancer	0.00018	0.000627	CcSEcCtD
Raloxifene—Abdominal pain—Paclitaxel—kidney cancer	0.000179	0.000625	CcSEcCtD
Raloxifene—Body temperature increased—Paclitaxel—kidney cancer	0.000179	0.000625	CcSEcCtD
Raloxifene—Headache—Vincristine—kidney cancer	0.000179	0.000623	CcSEcCtD
Raloxifene—Sinusitis—Doxorubicin—kidney cancer	0.000177	0.000615	CcSEcCtD
Raloxifene—Vomiting—Gemcitabine—kidney cancer	0.000172	0.0006	CcSEcCtD
Raloxifene—Rash—Gemcitabine—kidney cancer	0.000171	0.000595	CcSEcCtD
Raloxifene—Dermatitis—Gemcitabine—kidney cancer	0.000171	0.000595	CcSEcCtD
Raloxifene—Headache—Gemcitabine—kidney cancer	0.00017	0.000591	CcSEcCtD
Raloxifene—Nausea—Vincristine—kidney cancer	0.00017	0.000591	CcSEcCtD
Raloxifene—Musculoskeletal discomfort—Capecitabine—kidney cancer	0.00017	0.000591	CcSEcCtD
Raloxifene—Rhinitis—Doxorubicin—kidney cancer	0.000169	0.00059	CcSEcCtD
Raloxifene—Insomnia—Capecitabine—kidney cancer	0.000169	0.000587	CcSEcCtD
Raloxifene—Hypoaesthesia—Doxorubicin—kidney cancer	0.000168	0.000586	CcSEcCtD
Raloxifene—Pharyngitis—Doxorubicin—kidney cancer	0.000168	0.000584	CcSEcCtD
Raloxifene—Urinary tract disorder—Doxorubicin—kidney cancer	0.000167	0.000581	CcSEcCtD
Raloxifene—Oedema peripheral—Doxorubicin—kidney cancer	0.000167	0.00058	CcSEcCtD
Raloxifene—Connective tissue disorder—Doxorubicin—kidney cancer	0.000166	0.000578	CcSEcCtD
Raloxifene—Urethral disorder—Doxorubicin—kidney cancer	0.000166	0.000577	CcSEcCtD
Raloxifene—Dyspepsia—Capecitabine—kidney cancer	0.000164	0.000571	CcSEcCtD
Raloxifene—Nausea—Gemcitabine—kidney cancer	0.000161	0.000561	CcSEcCtD
Raloxifene—Gastrointestinal disorder—Capecitabine—kidney cancer	0.000161	0.00056	CcSEcCtD
Raloxifene—Pain—Capecitabine—kidney cancer	0.000159	0.000555	CcSEcCtD
Raloxifene—Flushing—Doxorubicin—kidney cancer	0.000157	0.000546	CcSEcCtD
Raloxifene—Cardiac disorder—Doxorubicin—kidney cancer	0.000157	0.000546	CcSEcCtD
Raloxifene—Diarrhoea—Paclitaxel—kidney cancer	0.000155	0.000541	CcSEcCtD
Raloxifene—Angiopathy—Doxorubicin—kidney cancer	0.000153	0.000534	CcSEcCtD
Raloxifene—Gastrointestinal pain—Capecitabine—kidney cancer	0.000152	0.00053	CcSEcCtD
Raloxifene—Dizziness—Paclitaxel—kidney cancer	0.00015	0.000523	CcSEcCtD
Raloxifene—Body temperature increased—Capecitabine—kidney cancer	0.000147	0.000513	CcSEcCtD
Raloxifene—Abdominal pain—Capecitabine—kidney cancer	0.000147	0.000513	CcSEcCtD
Raloxifene—Flatulence—Doxorubicin—kidney cancer	0.000145	0.000505	CcSEcCtD
Raloxifene—Vomiting—Paclitaxel—kidney cancer	0.000144	0.000503	CcSEcCtD
Raloxifene—Rash—Paclitaxel—kidney cancer	0.000143	0.000498	CcSEcCtD
Raloxifene—Dermatitis—Paclitaxel—kidney cancer	0.000143	0.000498	CcSEcCtD
Raloxifene—Headache—Paclitaxel—kidney cancer	0.000142	0.000495	CcSEcCtD
Raloxifene—Muscle spasms—Doxorubicin—kidney cancer	0.000141	0.000493	CcSEcCtD
Raloxifene—Nausea—Paclitaxel—kidney cancer	0.000135	0.000469	CcSEcCtD
Raloxifene—Vertigo—Doxorubicin—kidney cancer	0.000132	0.00046	CcSEcCtD
Raloxifene—Syncope—Doxorubicin—kidney cancer	0.000132	0.000459	CcSEcCtD
Raloxifene—Loss of consciousness—Doxorubicin—kidney cancer	0.000129	0.00045	CcSEcCtD
Raloxifene—Cough—Doxorubicin—kidney cancer	0.000128	0.000447	CcSEcCtD
Raloxifene—Diarrhoea—Capecitabine—kidney cancer	0.000127	0.000444	CcSEcCtD
Raloxifene—Chest pain—Doxorubicin—kidney cancer	0.000125	0.000436	CcSEcCtD
Raloxifene—Arthralgia—Doxorubicin—kidney cancer	0.000125	0.000436	CcSEcCtD
Raloxifene—Myalgia—Doxorubicin—kidney cancer	0.000125	0.000436	CcSEcCtD
Raloxifene—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	0.000124	0.000433	CcSEcCtD
Raloxifene—Dizziness—Capecitabine—kidney cancer	0.000123	0.000429	CcSEcCtD
Raloxifene—Infection—Doxorubicin—kidney cancer	0.000119	0.000415	CcSEcCtD
Raloxifene—Vomiting—Capecitabine—kidney cancer	0.000118	0.000412	CcSEcCtD
Raloxifene—Shock—Doxorubicin—kidney cancer	0.000118	0.000411	CcSEcCtD
Raloxifene—Nervous system disorder—Doxorubicin—kidney cancer	0.000118	0.00041	CcSEcCtD
Raloxifene—Thrombocytopenia—Doxorubicin—kidney cancer	0.000118	0.000409	CcSEcCtD
Raloxifene—Rash—Capecitabine—kidney cancer	0.000117	0.000409	CcSEcCtD
Raloxifene—Dermatitis—Capecitabine—kidney cancer	0.000117	0.000409	CcSEcCtD
Raloxifene—Headache—Capecitabine—kidney cancer	0.000117	0.000406	CcSEcCtD
Raloxifene—Skin disorder—Doxorubicin—kidney cancer	0.000117	0.000406	CcSEcCtD
Raloxifene—Hyperhidrosis—Doxorubicin—kidney cancer	0.000116	0.000404	CcSEcCtD
Raloxifene—Nausea—Capecitabine—kidney cancer	0.000111	0.000385	CcSEcCtD
Raloxifene—Musculoskeletal discomfort—Doxorubicin—kidney cancer	0.000109	0.000381	CcSEcCtD
Raloxifene—Insomnia—Doxorubicin—kidney cancer	0.000109	0.000378	CcSEcCtD
Raloxifene—Dyspepsia—Doxorubicin—kidney cancer	0.000106	0.000368	CcSEcCtD
Raloxifene—Gastrointestinal disorder—Doxorubicin—kidney cancer	0.000104	0.000361	CcSEcCtD
Raloxifene—Pain—Doxorubicin—kidney cancer	0.000103	0.000358	CcSEcCtD
Raloxifene—Gastrointestinal pain—Doxorubicin—kidney cancer	9.82e-05	0.000342	CcSEcCtD
Raloxifene—Abdominal pain—Doxorubicin—kidney cancer	9.49e-05	0.000331	CcSEcCtD
Raloxifene—Body temperature increased—Doxorubicin—kidney cancer	9.49e-05	0.000331	CcSEcCtD
Raloxifene—Diarrhoea—Doxorubicin—kidney cancer	8.22e-05	0.000286	CcSEcCtD
Raloxifene—Dizziness—Doxorubicin—kidney cancer	7.94e-05	0.000276	CcSEcCtD
Raloxifene—Vomiting—Doxorubicin—kidney cancer	7.64e-05	0.000266	CcSEcCtD
Raloxifene—Rash—Doxorubicin—kidney cancer	7.57e-05	0.000264	CcSEcCtD
Raloxifene—Dermatitis—Doxorubicin—kidney cancer	7.57e-05	0.000263	CcSEcCtD
Raloxifene—Headache—Doxorubicin—kidney cancer	7.52e-05	0.000262	CcSEcCtD
Raloxifene—Nausea—Doxorubicin—kidney cancer	7.13e-05	0.000248	CcSEcCtD
Raloxifene—CYP19A1—Metabolism—SCARB1—kidney cancer	2.81e-05	0.000286	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—PTGS1—kidney cancer	2.78e-05	0.000283	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—ALDH1A1—kidney cancer	2.75e-05	0.000279	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—PSMD7—kidney cancer	2.73e-05	0.000278	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—ACY1—kidney cancer	2.69e-05	0.000274	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—TSC1—kidney cancer	2.69e-05	0.000273	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—PSMD7—kidney cancer	2.69e-05	0.000273	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—ANXA1—kidney cancer	2.69e-05	0.000273	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—CTNNA1—kidney cancer	2.65e-05	0.00027	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—CA9—kidney cancer	2.65e-05	0.000269	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—EIF4EBP1—kidney cancer	2.64e-05	0.000268	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—HSPB1—kidney cancer	2.64e-05	0.000268	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—PGK1—kidney cancer	2.63e-05	0.000268	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—SLC5A3—kidney cancer	2.63e-05	0.000268	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—GRB7—kidney cancer	2.62e-05	0.000267	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—FLT1—kidney cancer	2.6e-05	0.000265	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—BCHE—kidney cancer	2.59e-05	0.000263	CbGpPWpGaD
Raloxifene—AOX1—Metabolism—POMC—kidney cancer	2.59e-05	0.000263	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—LDHB—kidney cancer	2.58e-05	0.000263	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—SLC5A5—kidney cancer	2.56e-05	0.00026	CbGpPWpGaD
Raloxifene—AOX1—Disease—RAF1—kidney cancer	2.55e-05	0.000259	CbGpPWpGaD
Raloxifene—AOX1—Disease—ERBB2—kidney cancer	2.52e-05	0.000256	CbGpPWpGaD
Raloxifene—AOX1—Disease—MTOR—kidney cancer	2.49e-05	0.000253	CbGpPWpGaD
Raloxifene—AOX1—Disease—CD4—kidney cancer	2.48e-05	0.000252	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—SLC2A1—kidney cancer	2.47e-05	0.000251	CbGpPWpGaD
Raloxifene—AOX1—Disease—PTGS2—kidney cancer	2.46e-05	0.00025	CbGpPWpGaD
Raloxifene—HTR6—GPCR downstream signaling—POMC—kidney cancer	2.45e-05	0.00025	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—PSMD7—kidney cancer	2.45e-05	0.000249	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—TSC1—kidney cancer	2.45e-05	0.000249	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—ANXA1—kidney cancer	2.45e-05	0.000249	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—ITPR2—kidney cancer	2.44e-05	0.000248	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—PAK1—kidney cancer	2.41e-05	0.000245	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—JUNB—kidney cancer	2.41e-05	0.000245	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	2.4e-05	0.000244	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—FLT1—kidney cancer	2.38e-05	0.000242	CbGpPWpGaD
Raloxifene—AOX1—Disease—CDKN1B—kidney cancer	2.33e-05	0.000237	CbGpPWpGaD
Raloxifene—ESR1—Gene Expression—CDKN2B—kidney cancer	2.3e-05	0.000234	CbGpPWpGaD
Raloxifene—EBP—Metabolism—PIK3CA—kidney cancer	2.29e-05	0.000233	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—PDHB—kidney cancer	2.29e-05	0.000233	CbGpPWpGaD
Raloxifene—CYP3A4—Biological oxidations—POMC—kidney cancer	2.28e-05	0.000232	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—CRABP1—kidney cancer	2.25e-05	0.000229	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—CA9—kidney cancer	2.24e-05	0.000228	CbGpPWpGaD
Raloxifene—HTR2B—GPCR downstream signaling—POMC—kidney cancer	2.24e-05	0.000228	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—POMC—kidney cancer	2.23e-05	0.000227	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—CTNNA1—kidney cancer	2.21e-05	0.000225	CbGpPWpGaD
Raloxifene—AOX1—Disease—CTNNB1—kidney cancer	2.2e-05	0.000224	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—JUNB—kidney cancer	2.2e-05	0.000224	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—PAK1—kidney cancer	2.2e-05	0.000224	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—EIF4EBP1—kidney cancer	2.2e-05	0.000224	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—HSPB1—kidney cancer	2.2e-05	0.000224	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism of lipids and lipoproteins—CYP1A1—kidney cancer	2.19e-05	0.000223	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—CCBL1—kidney cancer	2.15e-05	0.000219	CbGpPWpGaD
Raloxifene—AOX1—Disease—PTEN—kidney cancer	2.15e-05	0.000218	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—ITPR2—kidney cancer	2.09e-05	0.000213	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	2.09e-05	0.000212	CbGpPWpGaD
Raloxifene—AOX1—Metabolism—PTGS2—kidney cancer	2.06e-05	0.00021	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—GSTP1—kidney cancer	2.06e-05	0.000209	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—TSC1—kidney cancer	2.04e-05	0.000208	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—PSMD7—kidney cancer	2.04e-05	0.000208	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—ANXA1—kidney cancer	2.04e-05	0.000208	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—POMC—kidney cancer	2.03e-05	0.000207	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—FLT1—kidney cancer	1.98e-05	0.000201	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—IGF2—kidney cancer	1.97e-05	0.000201	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—CDKN2B—kidney cancer	1.96e-05	0.0002	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—ABCB1—kidney cancer	1.95e-05	0.000198	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—GSTT1—kidney cancer	1.91e-05	0.000194	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—ACHE—kidney cancer	1.91e-05	0.000194	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—IGF1R—kidney cancer	1.91e-05	0.000194	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—CRABP1—kidney cancer	1.9e-05	0.000194	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—GSTM1—kidney cancer	1.89e-05	0.000192	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—PPAT—kidney cancer	1.87e-05	0.00019	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—GLIPR1—kidney cancer	1.87e-05	0.00019	CbGpPWpGaD
Raloxifene—ESR1—Generic Transcription Pathway—MYC—kidney cancer	1.85e-05	0.000188	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—RAF1—kidney cancer	1.84e-05	0.000187	CbGpPWpGaD
Raloxifene—AOX1—Disease—MAPK3—kidney cancer	1.84e-05	0.000187	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—PAK1—kidney cancer	1.83e-05	0.000187	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—JUNB—kidney cancer	1.83e-05	0.000187	CbGpPWpGaD
Raloxifene—ESR2—Gene Expression—MAPK3—kidney cancer	1.81e-05	0.000185	CbGpPWpGaD
Raloxifene—HTR6—GPCR downstream signaling—IL2—kidney cancer	1.81e-05	0.000185	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—SCARB1—kidney cancer	1.81e-05	0.000184	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—IGF2—kidney cancer	1.8e-05	0.000183	CbGpPWpGaD
Raloxifene—AOX1—Metabolism—PTEN—kidney cancer	1.8e-05	0.000183	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—CYP1A1—kidney cancer	1.79e-05	0.000182	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—CDKN2B—kidney cancer	1.79e-05	0.000182	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—PTGS1—kidney cancer	1.79e-05	0.000182	CbGpPWpGaD
Raloxifene—AOX1—Disease—MYC—kidney cancer	1.78e-05	0.000182	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—ITPR2—kidney cancer	1.77e-05	0.00018	CbGpPWpGaD
Raloxifene—ESR2—Gene Expression—MYC—kidney cancer	1.77e-05	0.000179	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—PSMD7—kidney cancer	1.75e-05	0.000178	CbGpPWpGaD
Raloxifene—AOX1—Disease—MAPK1—kidney cancer	1.75e-05	0.000178	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—IGF1R—kidney cancer	1.74e-05	0.000177	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—FH—kidney cancer	1.73e-05	0.000176	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—APRT—kidney cancer	1.73e-05	0.000176	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—RAF1—kidney cancer	1.68e-05	0.000171	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—BCHE—kidney cancer	1.66e-05	0.000169	CbGpPWpGaD
Raloxifene—HTR2B—GPCR downstream signaling—IL2—kidney cancer	1.66e-05	0.000168	CbGpPWpGaD
Raloxifene—AOX1—Disease—KRAS—kidney cancer	1.65e-05	0.000168	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—IL2—kidney cancer	1.65e-05	0.000168	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—SLC5A5—kidney cancer	1.64e-05	0.000167	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism of lipids and lipoproteins—POMC—kidney cancer	1.63e-05	0.000166	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—GPC3—kidney cancer	1.63e-05	0.000166	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—GSTT1—kidney cancer	1.61e-05	0.000164	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—ACHE—kidney cancer	1.61e-05	0.000164	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—CA2—kidney cancer	1.59e-05	0.000161	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—SLC2A1—kidney cancer	1.59e-05	0.000161	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—HIF1A—kidney cancer	1.57e-05	0.00016	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—TSC2—kidney cancer	1.57e-05	0.000159	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—ALAD—kidney cancer	1.55e-05	0.000157	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—SCARB1—kidney cancer	1.53e-05	0.000155	CbGpPWpGaD
Raloxifene—AOX1—Disease—PIK3CA—kidney cancer	1.52e-05	0.000154	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—PTGS1—kidney cancer	1.51e-05	0.000154	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—ST3GAL2—kidney cancer	1.51e-05	0.000153	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—IL2—kidney cancer	1.5e-05	0.000153	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—KDR—kidney cancer	1.5e-05	0.000153	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—IGF2—kidney cancer	1.5e-05	0.000153	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—CDKN2B—kidney cancer	1.49e-05	0.000152	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—PSMD7—kidney cancer	1.48e-05	0.000151	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—ALDH1A1—kidney cancer	1.48e-05	0.00015	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	1.47e-05	0.00015	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—IGF1R—kidney cancer	1.45e-05	0.000147	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—HIF1A—kidney cancer	1.43e-05	0.000146	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—TSC2—kidney cancer	1.43e-05	0.000145	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—PGK1—kidney cancer	1.41e-05	0.000144	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—SLC5A3—kidney cancer	1.41e-05	0.000144	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—BCHE—kidney cancer	1.41e-05	0.000143	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—SLC5A5—kidney cancer	1.39e-05	0.000141	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—LDHB—kidney cancer	1.39e-05	0.000141	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—KIT—kidney cancer	1.38e-05	0.000141	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—APC—kidney cancer	1.38e-05	0.000141	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—KDR—kidney cancer	1.37e-05	0.000139	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—SLC2A1—kidney cancer	1.34e-05	0.000136	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—POMC—kidney cancer	1.34e-05	0.000136	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—MAPK3—kidney cancer	1.32e-05	0.000135	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—GSTP1—kidney cancer	1.32e-05	0.000134	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—POMC—kidney cancer	1.32e-05	0.000134	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	1.3e-05	0.000132	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—BRAF—kidney cancer	1.3e-05	0.000132	CbGpPWpGaD
Raloxifene—AOX1—Metabolism—PIK3CA—kidney cancer	1.27e-05	0.000129	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—APC—kidney cancer	1.26e-05	0.000128	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—KIT—kidney cancer	1.26e-05	0.000128	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—MAPK1—kidney cancer	1.26e-05	0.000128	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—ABCB1—kidney cancer	1.25e-05	0.000127	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—GSTM1—kidney cancer	1.22e-05	0.000124	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—MAPK3—kidney cancer	1.21e-05	0.000123	CbGpPWpGaD
Raloxifene—HTR6—GPCR downstream signaling—PIK3CA—kidney cancer	1.2e-05	0.000122	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—CA9—kidney cancer	1.2e-05	0.000122	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—POMC—kidney cancer	1.2e-05	0.000122	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—HIF1A—kidney cancer	1.19e-05	0.000121	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—TSC2—kidney cancer	1.19e-05	0.000121	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—KRAS—kidney cancer	1.19e-05	0.000121	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—BRAF—kidney cancer	1.19e-05	0.000121	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—CYP1A1—kidney cancer	1.15e-05	0.000117	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—MAPK1—kidney cancer	1.15e-05	0.000117	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—KDR—kidney cancer	1.14e-05	0.000116	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	1.14e-05	0.000115	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—GSTP1—kidney cancer	1.12e-05	0.000114	CbGpPWpGaD
Raloxifene—HTR2B—GPCR downstream signaling—PIK3CA—kidney cancer	1.1e-05	0.000112	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—PIK3CA—kidney cancer	1.09e-05	0.000111	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—KRAS—kidney cancer	1.09e-05	0.00011	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—RAF1—kidney cancer	1.09e-05	0.00011	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—RELA—kidney cancer	1.08e-05	0.00011	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—ERBB2—kidney cancer	1.07e-05	0.000109	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—PTGS2—kidney cancer	1.07e-05	0.000108	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—MTOR—kidney cancer	1.06e-05	0.000108	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—ABCB1—kidney cancer	1.06e-05	0.000108	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—KIT—kidney cancer	1.05e-05	0.000107	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—APC—kidney cancer	1.05e-05	0.000107	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—GSTM1—kidney cancer	1.03e-05	0.000105	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—CRABP1—kidney cancer	1.02e-05	0.000104	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—POMC—kidney cancer	1e-05	0.000102	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—PIK3CA—kidney cancer	9.98e-06	0.000102	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—CDKN1B—kidney cancer	9.95e-06	0.000101	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—RAF1—kidney cancer	9.91e-06	0.000101	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—BRAF—kidney cancer	9.89e-06	0.000101	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—RELA—kidney cancer	9.86e-06	0.0001	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—ERBB2—kidney cancer	9.8e-06	9.97e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—CYP1A1—kidney cancer	9.75e-06	9.92e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—IL2—kidney cancer	9.73e-06	9.9e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—MTOR—kidney cancer	9.67e-06	9.84e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—ITPR2—kidney cancer	9.51e-06	9.67e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—CCND1—kidney cancer	9.49e-06	9.65e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—JUN—kidney cancer	9.47e-06	9.63e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—CTNNB1—kidney cancer	9.4e-06	9.55e-05	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—PTEN—kidney cancer	9.3e-06	9.46e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—PTEN—kidney cancer	9.16e-06	9.31e-05	CbGpPWpGaD
Raloxifene—ESR1—Gene Expression—MAPK3—kidney cancer	9.15e-06	9.31e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—CDKN1B—kidney cancer	9.08e-06	9.23e-05	CbGpPWpGaD
Raloxifene—ESR1—Gene Expression—MYC—kidney cancer	8.9e-06	9.05e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—IL2—kidney cancer	8.88e-06	9.03e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—GSTT1—kidney cancer	8.67e-06	8.81e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—ACHE—kidney cancer	8.67e-06	8.81e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—CCND1—kidney cancer	8.66e-06	8.81e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—JUN—kidney cancer	8.64e-06	8.79e-05	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—POMC—kidney cancer	8.59e-06	8.73e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—CTNNB1—kidney cancer	8.58e-06	8.72e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—PTEN—kidney cancer	8.36e-06	8.5e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—VEGFA—kidney cancer	8.27e-06	8.41e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—RAF1—kidney cancer	8.25e-06	8.39e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—RELA—kidney cancer	8.22e-06	8.36e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—SCARB1—kidney cancer	8.21e-06	8.34e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—ERBB2—kidney cancer	8.17e-06	8.3e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—PTGS1—kidney cancer	8.12e-06	8.26e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—MTOR—kidney cancer	8.06e-06	8.19e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	8.01e-06	8.15e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—PSMD7—kidney cancer	7.97e-06	8.1e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—MAPK3—kidney cancer	7.82e-06	7.96e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—MYC—kidney cancer	7.61e-06	7.74e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—CDKN1B—kidney cancer	7.56e-06	7.69e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—BCHE—kidney cancer	7.55e-06	7.68e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—VEGFA—kidney cancer	7.55e-06	7.68e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—SLC5A5—kidney cancer	7.46e-06	7.59e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—MAPK1—kidney cancer	7.45e-06	7.57e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—IL2—kidney cancer	7.4e-06	7.53e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—POMC—kidney cancer	7.27e-06	7.39e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—CCND1—kidney cancer	7.21e-06	7.34e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—SLC2A1—kidney cancer	7.2e-06	7.33e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—JUN—kidney cancer	7.2e-06	7.32e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—CTNNB1—kidney cancer	7.14e-06	7.27e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—MAPK3—kidney cancer	7.14e-06	7.26e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—KRAS—kidney cancer	7.03e-06	7.15e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—PTEN—kidney cancer	6.96e-06	7.08e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—MYC—kidney cancer	6.95e-06	7.06e-05	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—PTGS2—kidney cancer	6.85e-06	6.97e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—MAPK1—kidney cancer	6.8e-06	6.91e-05	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—PIK3CA—kidney cancer	6.56e-06	6.67e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—PIK3CA—kidney cancer	6.46e-06	6.57e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—KRAS—kidney cancer	6.42e-06	6.53e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—VEGFA—kidney cancer	6.29e-06	6.4e-05	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—TP53—kidney cancer	6.25e-06	6.36e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—GSTP1—kidney cancer	6.01e-06	6.11e-05	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—PTEN—kidney cancer	5.97e-06	6.07e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—MAPK3—kidney cancer	5.95e-06	6.05e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—PIK3CA—kidney cancer	5.9e-06	6e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—PTGS2—kidney cancer	5.8e-06	5.9e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—MYC—kidney cancer	5.79e-06	5.88e-05	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—TP53—kidney cancer	5.71e-06	5.8e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—ABCB1—kidney cancer	5.69e-06	5.78e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—MAPK1—kidney cancer	5.66e-06	5.76e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—GSTM1—kidney cancer	5.52e-06	5.61e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—KRAS—kidney cancer	5.35e-06	5.44e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—CYP1A1—kidney cancer	5.23e-06	5.32e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—PTEN—kidney cancer	5.06e-06	5.14e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—PIK3CA—kidney cancer	4.91e-06	5e-05	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—TP53—kidney cancer	4.75e-06	4.83e-05	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—PIK3CA—kidney cancer	4.21e-06	4.29e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—POMC—kidney cancer	3.9e-06	3.97e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—PIK3CA—kidney cancer	3.57e-06	3.63e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—PTGS2—kidney cancer	3.11e-06	3.17e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—PTEN—kidney cancer	2.71e-06	2.76e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—PIK3CA—kidney cancer	1.92e-06	1.95e-05	CbGpPWpGaD
